source
- Novo acquires three early-stage obesity assets from Kallyope to broaden pipeline amid investor pressureInvestors have been urging Novo to expand its pipeline beyond the semaglutide franchise that drives most of its sales. In response, Novo announced it will acquire three early-stage obesity candida…
- TRex Bio and Retension Pharma announce plans for IPOs, outlining biotech pipeline fundingBiotech companies Retension Pharmaceuticals and TRex Bio have filed with the SEC indicating they intend to go public this year, adding to the current wave of biotech IPOs. TRex Bio said it will us…